Evidence map›Paper›PMID 42477786›Full record

ArticleBiology direct2026

4-phenylbutyric acid-loaded mesoporous silica nanoparticles alleviate endoplasmic reticulum stress and reduce intraocular pressure in glaucoma model.

Xuejing Yan, Wu Qin, Xiaoming Gan, Yingyan Mao, Shen Wu, Shipeng Wen, Jingxue Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biology direct, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xuejing Yan *Beijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Beijing Key Laboratory of Intelligent Diagnosis Technology and Equipment for Optic Nerve-Related Eye Diseases, Capital Medical University, Beijing, 100730, China.
Wu Qin *State Key Laboratory of Organic-Inorganic Composites, Beijing University of Chemical Technology, Beijing, 100029, China.
Xiaoming GanNational Engineering Research Center for Rare Earth, Grirem Advanced Materials Co., Ltd., Beijing, 100088, China.
Yingyan MaoBeijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Beijing Key Laboratory of Intelligent Diagnosis Technology and Equipment for Optic Nerve-Related Eye Diseases, Capital Medical University, Beijing, 100730, China.
Shen WuBeijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Beijing Key Laboratory of Intelligent Diagnosis Technology and Equipment for Optic Nerve-Related Eye Diseases, Capital Medical University, Beijing, 100730, China.
Shipeng WenState Key Laboratory of Organic-Inorganic Composites, Beijing University of Chemical Technology, Beijing, 100029, China. wensp@mail.buct.edu.cn.
Jingxue ZhangBeijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Beijing Key Laboratory of Intelligent Diagnosis Technology and Equipment for Optic Nerve-Related Eye Diseases, Capital Medical University, Beijing, 100730, China. jingxuezh@ccmu.edu.cn.ORCID https://orcid.org/0000-0002-9512-9602

Funding

Beijing Natural Science Foundation L212036National Natural Science Foundation of China 82301195
6 · The paper itself

Abstract

purposeTo develop a mesoporous silica nanoparticle-based delivery system for 4-phenylbutyric acid (4-PBA) and evaluate its potential to alleviate endoplasmic reticulum (ER) stress and improve mutant myocilin (MYOC)-associated glaucoma. MATERIALS AND

methodsWe synthesized hollow/snowflake-like mesoporous silica nanoparticles loaded with 4-PBA (mSiO₂-PBA) for drug loading and release. Cellular uptake and cytotoxicity were evaluated in human corneal epithelial cells (HCECs) and human trabecular meshwork cells (HTMCs). The effects of mSiO₂-PBA on mutant MYOC secretion and ER stress-associated proteins were assessed by Western blot analysis. In Tg-MYOC

resultsmSiO₂-PBA exhibited efficient cellular uptake and favorable biocompatibility in vitro. Treatment with mSiO₂-PBA enhanced mutant MYOC secretion and reduced ER stress-associated KDEL-positive proteins in HTMCs. Following topical administration, mSiO₂-PBA achieved ocular penetration and exposure in trabecular meshwork tissue. In Tg-MYOC

conclusionsmSiO₂-PBA represents a promising nanoparticle-based delivery platform for 4-PBA in MYOC-associated glaucoma. By promoting mutant MYOC secretion and alleviating ER stress, mSiO₂-PBA demonstrated therapeutic efficacy in vitro and in vivo, supporting its potential as a nanotherapeutic strategy for MYOC-associated glaucoma.

Indexed as

Endoplasmic Reticulum StressGlaucomaIntraocular PressureNanoparticlesPhenylbutyratesSilicon DioxideAnimalsCytoskeletal ProteinsDisease Models, AnimalEye ProteinsGlycoproteinsHumansMiceMyocilinTrabecular Meshwork4-phenylbutyric acidCytoskeletal ProteinsEye ProteinsGlycoproteinsMyocilinPhenylbutyratesSilicon DioxideGlaucomamSiO₂-PBAMYOCTrabecular meshwork

Identifiers

PMID42477786
PMCPMC13679216

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.